Hyponatraemia in heart failure: time for new solutions?

Authors:

Abstract
Hyponatraemia is very common in heart failure (HF), especially in decompensated patients. It is associated with increased mortality and morbidity and considered a marker of advanced disease. Recognition of hyponatraemia and its causes may help guide treatment strategy. Historically, therapy has primarily focused on water restriction, decongestion with loop diuretics in case of volume overload (dilutional hyponatraemia) and sodium repletion in case of depletion. In this review, we summarise the potential benefits of established and emerging HF therapies on sodium homeostasis, with a focus on dual vasopressin antagonists, angiotensin receptor-neprilysin inhibitors, sodium-glucose cotransporter 2 inhibitors and hypertonic saline, and propose a potential therapeutic approach for hyponatraemia in HF.
Funding Information
  • Ministry of Science and Higher Education of the Russian Federation (agreement #075-15-2020-800)
  • the Special Research Fund (BOF) of Hasselt University (BOF19PD04)

This publication has 47 references indexed in Scilit: